How to Use Survodutide
Complete guide to Survodutide dosing, administration, timing, and protocol recommendations.
Quick Overview
Survodutide is an injectable dual agonist that hits both the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim and Zealand Pharma. It is being tested for obesity and for fatty liver disease (MASH), and it carries an FDA Breakthrough Therapy designation for MASH. It is still investigational and not approved for any use as of mid-2026.
Dosing Guidelines
Common Dose
Limited community data available
Frequency
See research protocols
Dose Range
See research dosing
Note: Limited anecdotal data. Refer to research dosing section.
Administration Method
Subcutaneous injection weekly
Best Time to Take
Before bed or morning (fasted)
GH-related peptides work best on an empty stomach to maximize growth hormone release.
Protocol Duration
Long-term use expected
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea (55-75%)
- •Vomiting (41%)
- •Diarrhea (49%)
- •Constipation
- •GI effects during dose escalation
Frequently Asked Questions
What is the recommended dose for Survodutide?
Limited community data available
How do you administer Survodutide?
Subcutaneous injection weekly
When is the best time to take Survodutide?
Before bed or morning (fasted)
How long should you use Survodutide?
Long-term use expected
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.